November 19, 2020

Impact: High

  • Results for Affimed’s AFM13 (CD30/CD16A ICE; Innate Cell Engager) in combination with Keytruda (pembrolizumab) in a phase 1b study for r/r Hodgkin Lymphoma patients have been published in the journal Blood. Key efficacy data included (n=30):
    • ORR (Objective Response Rate): 88% (CR rate: 46%) at the recommended dose level
  • Investigators deemed the combination to be safe and well tolerated with adverse events that were manageable.

Read more